News

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, FLORIDA & STOCKHOLM, SWEDEN – October 22, 2020 – Vycellix, Inc., an immuno-centric ...
Read More

Vycellix CEO to Present Next-Generation Universal Cell Platform to Optimize Allogeneic Cell Therapies at ‘Innate Killer Summit’

VY-UC represents novel & simplified approach to design “off-the-shelf” therapies resolving the complexities & limitations of gene-editing to modulate self-recognition proteins  TAMPA, FLORIDA & STOCKHOLM, SWEDEN – August 10, 2020 – Vycellix, Inc., an immuno-centric discovery life science company with ...
Read More

Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies

TAMPA, FLORIDA & DUBLIN, IRELAND – March 25, 2020 – Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to ...
Read More

Vycellix Founders Awarded Major Swedish Grant to Establish NextGen-NK

Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners TAMPA, ...
Read More

Vycellix Announces Formation of Scientific Advisory Board

SAB Comprised of Key Opinion Leaders Advancing Next-Generation Cell & Gene-based Immuno-Oncology Therapeutic Platforms TAMPA, FLORIDA & STOCKHOLM, SWEDEN – June 25, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned ...
Read More

Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit

TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will present at the Innate Killer Summit 2019 to be held in ...
Read More

Cell & Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa

Vycellix is advancing pipeline of modulators and next-generation T cell & NK cell therapies for treatment of cancers Company to present on Cell Therapy Manufacturing Panel at Moffitt’s Business of Biotech Conference on Feb 22 TAMPA, FLORIDA & STOCKHOLM, SWEDEN ...
Read More

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 – Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cellular therapies, ...
Read More

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

New Products Enhance Genetic Modification of Lymphocytes and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus ...
Read More